The Lynx Group
Cholangiocarcinoma News

GemCis with or without CPI-613 as First-Line Therapy for Patients with Advanced BTCs: The BilT-04 Study

September 2022, Vol 3, No 3

Patients with advanced biliary tract cancers (BTCs) have a poor prognosis despite systemic chemotherapy. Gemcitabine/cisplatin (GemCis) is the standard first-line systemic therapy for BTCs; however, median overall survival was only 11.7 months. CPI-613 (devimistat) is a stable intermediate of a lipoate analog that is a specific inhibitor of key enzymes of the tricarboxylic cycle within the mitochondria of cancer cells, leading to increased chemotherapeutic cytotoxicity. To improve efficacy outcomes, an ongoing investigator-initiated, multi-institutional, phase 1b/2 trial (BilT-04) is evaluating the addition of CPI-613 to the standard GemCis backbone in patients with previously untreated advanced BTCs. Results of the phase 1b portion of the study were reported at the 2022 ASCO annual meeting.

The primary objective of the phase 1b portion was to determine the recommended phase 2 dose (RP2D). Patients received combination GemCis (gemcitabine 1000 mg/m2, cisplatin 25 mg/m2) plus CPI-613 at various dose levels on days 1 and 8 every 21 days; the phase 1b dose levels of CPI-613 were 500 mg/m2 (dose level –1), 1000 mg/m2 (dose level 1), 1500 mg/m2 (dose level 2), and 2000 mg/m2 (dose level 3).

A total of 20 patients were included in this analysis. Of these, 1 patient each was assigned to dose levels –1 and 1, 2 patients to dose level 2, and 16 patients to dose level 3. The median age of the study population was 65 years (range, 43-75 years); 55% were men, 85% were Caucasian, 45% had ECOG performance status 0, and 75% had metastatic disease. Of the 20 patients, 9 had a diagnosis of intrahepatic cholangiocarcinoma (CCA), 5 had hilar CCA, 2 had distal CCA, and 3 had gallbladder cancer.

A dose-limiting toxicity of grade 2 creatinine elevation was reported in only 1 patient at dose level 3 (2000 mg/m2), so the RP2D for CPI-613 was established as 2000 mg/m2. In the total population of phase 1b, the objective response rate was 45%, including 1 complete response and 7 partial responses. Median progression-free survival was 14.9 months (95% confidence interval, 7.4-16.0), with 7 patients still on treatment. Overall survival was not yet estimable, with 15 patients still alive. Treatment-related serious adverse events were reported in 4 patients, including grade 3 febrile neutropenia (n = 2) and infection (n = 2).

Based on results of the phase 1b portion of the BilT-04 study, Sahai and colleagues concluded that the combination of CPI-613 plus GemCis was well-tolerated and that “CPI-613 in combination with gemcitabine and cisplatin may be active in this malignancy.” The randomized phase 2 portion of the trial is accruing patients at 10 sites, with enrollment expected to be completed in the third quarter of 2022.

Source: Sahai V, Zhen DB, Crysler OV, et al. Phase 1b results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- CPI-613 as first-line therapy for patients with advanced biliary tract cancer (BilT-04). Abstract 4094.

Related Items

Neoadjuvant Gemcitabine/Cisplatin/Nab-Paclitaxel for Resectable High-Risk iCCA: NEO-GAP
September 2022, Vol 3, No 3
For patients with localized intrahepatic cholangiocarcinoma (iCCA), surgical resection holds curative potential for only 30% to 35% of patients due to its high rate of recurrence.
Toripalimab Combined with Gemcitabine and S-1 in the First-Line Treatment of Advanced BTCs
September 2022, Vol 3, No 3
Although gemcitabine plus platinum/fluorouracil combinations are the standard first-line treatment for advanced biliary tract cancers (BTCs), the overall outcomes are suboptimal.
PROs with Durvalumab plus GemCis in Advanced BTCs: The TOPAZ-1 Study
September 2022, Vol 3, No 3
Results of the randomized, double-blind, global, phase 3 TOPAZ-1 trial demonstrated that the first-line chemoimmunotherapy regimen of the PD-L1 inhibitor durvalumab plus gemcitabine/cisplatin (GemCis; median follow-up, 16.8 months) significantly improved overall survival (OS) versus placebo plus GemCis (median follow-up, 15.9 months) in patients with advanced biliary tract cancers (BTCs).1
Regional Subgroup Analysis of Durvalumab plus GemCis in Advanced BTCs: The TOPAZ-1 Study
September 2022, Vol 3, No 3
The randomized, double-blind, global, phase 3 TOPAZ-1 trial demonstrated that the first-line PD-L1 inhibitor durvalumab plus gemcitabine/cisplatin (GemCis; median follow-up, 16.8 months) as first-line treatment significantly improved overall survival (OS) versus placebo plus GemCis (median follow-up, 15.9 months) in patients with advanced biliary tract cancers (BTCs).1
Preservation of Liver Function in Patients with Metastatic iCCA with Extrahepatic Disease
September 2022, Vol 3, No 3
Tumor-related liver failure (TRLF) is the most common cause of death in patients with metastatic intrahepatic cholangiocarcinoma (iCCA), accounting for up to 72% of deaths in patients treated with systemic therapy alone.1
Efficacy and Safety of Futibatinib in iCCA Harboring FGFR2 Fusions/Rearrangements: Updated Results of the FOENIX-CCA2 Trial
September 2022, Vol 3, No 3
Primary analysis of the pivotal, single-arm, phase 2 FOENIX-CCA2 study demonstrated that the FGFR1-4 inhibitor futibatinib as second-line treatment yielded durable objective responses in patients with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusion/rearrangements.
Adjuvant GemCis versus CAP in Patients with Resected Lymph Node–Positive eCCA: The STAMP Study
September 2022, Vol 3, No 3
Adjuvant capecitabine (CAP) is the current standard of care as adjuvant therapy for patients with resected cholangiocarcinoma (CCA); however, patient outcomes are still suboptimal.
CCA Summit Live from ASCO 2022
By Ghassan K. Abou-Alfa, MD, MBA
Videos
Dr Abou-Alfa also provides his perspective on the impact of the data on the management of patients with CCA.
Hot Topics in Cholangiocarcinoma and Biliary Tract Cancers: ASCO Highlights
September/October 2021, Vol 2, No 3
At the CCA Summit during the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO), Mitesh J. Borad, MD, Associate Professor of Medicine, Mayo Clinic, Phoenix, AZ, reviewed some of the key topics presented at ASCO 2021 related to cholangiocarcinoma (CCA) and other biliary tract cancers. Before turning to the specific presentations, Dr Borad welcomed the May 28, 2021, FDA approval of infigratinib (Truseltiq) for patients with advanced or metastatic CCA and FGFR2 fusions or rearrangements. Infigratinib follows pemigatinib (Pemazyre) as the second targeted therapy now available for this patient population.
CCA Summit Live from ASCO 2021
By Mitesh J. Borad, MD
Videos
On June 8, 2021, Dr Mitesh Borad, Associate Professor of Medicine at the Mayo Clinic in Phoenix, AZ, and a member of the Cholangiocarcinoma Summit Program Steering Committee, presented the top 15 abstracts on the management of cholangiocarcinoma and biliary tract cancer at ASCO 2021.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: